The story has been updated to include comments from an investment analyst.

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Qiagen announced on Sunday it has agreed to buy Australian biotech firm Cellestis for A$341 million ($355 million) in cash.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.

A company says it can generate likenesses of people based on their genetic profiles.

IBM's Watson is learning how to treat leukemia as a fellow at the MD Anderson Cancer Center, according to the Washington Post.

At her blog, Sally Rockey dives into National Institutes of Health funding data.